Ademi LLP is investigating Axonics (Nasdaq: AXNX) for possible breaches of fiduciary duty and other violations of law in its transaction with Boston Scientific.
In the transaction, Axonics stockholders will receive only $71 in cash per share, representing an equity value of approximately $3.7 billion. The transaction agreement unreasonably limits competing transactions for Axonics by imposing a significant penalty if Axonics accepts a competing bid. Axonics insiders will receive substantial benefits as part of change of control arrangements.
We are investigating the conduct of Axonics’ board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.